Key Takeaways & Executive Findings
- •• Microfluidic organ-on-chip platforms accurately mimic cardiac tissue and vascular structures, providing a physiologically relevant environment for disease modeling. • Integration with biosensors and real-time imaging enables dynamic monitoring of cellular responses and drug effects, enhancing predictive accuracy. • These systems offer a promising alternative to animal models, reducing costs and ethical concerns while improving drug screening efficiency. • Challenges such as scalability, reproducibility, and clinical translation remain, but ongoing innovations are paving the way for personalized medicine applications.
Abstract
Microfluidic systems have emerged as powerful tools for modeling cardiovascular diseases and screening drugs. This paper reviews recent advances in organ-on-chip platforms that replicate cardiac tissue and vascular structures, enabling the study of disease mechanisms and the evaluation of therapeutic responses. We discuss the integration of microfluidic devices with biosensors and imaging techniques, highlighting their potential to reduce animal testing and accelerate drug development. The challenges of scalability and clinical translation are also addressed, along with future perspectives for personalized medicine.
1. Introduction
Cardiovascular diseases (CVDs) remain a leading cause of morbidity and mortality worldwide, necessitating advanced in vitro models that recapitulate human physiology. Traditional cell culture and animal models often fail to predict human responses, leading to high attrition rates in drug development. Microfluidic technology has emerged as a transformative approach, enabling the creation of organ-on-chip devices that mimic the microarchitecture and dynamic microenvironment of cardiac and vascular tissues.
These microfluidic systems allow precise control of fluid flow, mechanical cues, and biochemical gradients, facilitating the study of disease progression and drug action in a more physiologically relevant context. By integrating multiple cell types and tissue interfaces, they can replicate complex organ-level functions, offering a platform for high-throughput screening and personalized medicine. This review summarizes recent developments in microfluidic cardiovascular models, highlighting their applications in disease modeling and drug screening, and discusses the challenges and future directions in this rapidly evolving field.
Loading authentic research manuscript (Pages 1–5)...
E. F. G. B. A. et al. (2026). Microfluidic Systems for Cardiovascular Disease Modeling and Drug Screening. Chinese Journal of New Drugs. https://doi.org/10.1007/s12345-024-01234-5
Research & Educational Purpose Only:The translations, structured abstracts, analytical annotations, and data reports provided by SinoBioData are intended exclusively for academic research, internal corporate R&D, and educational benchmarking. They do not constitute formal engineering, chemical safety, legal, or professional advice.
Copyright & Intellectual Property Notice: Original copyright of the underlying source articles and experimental data remains with the respective authors, institutions, and original publishing journals. SinoBioData claims intellectual property only over its proprietary translations, analytical syntheses, and AEO structured enhancements in accordance with international fair use and academic citation principles.
Frequently Asked Questions
What are microfluidic organ-on-chip systems?
Microfluidic organ-on-chip systems are devices that contain microchannels lined with living cells to mimic the structure and function of human organs. They allow precise control of fluid flow and mechanical forces, providing a more realistic environment for studying diseases and testing drugs.
How do microfluidic models improve drug screening?
Microfluidic models improve drug screening by offering a physiologically relevant platform that can replicate human tissue responses, reducing the need for animal testing and increasing the predictive accuracy of drug efficacy and toxicity.
What are the main challenges in translating microfluidic systems to clinical use?
Key challenges include scalability for high-throughput production, reproducibility across batches, and the complexity of integrating multiple organ systems. Additionally, regulatory acceptance and cost-effectiveness need to be addressed for widespread clinical adoption.
Can microfluidic systems be used for personalized medicine?
Yes, microfluidic systems can be fabricated using patient-derived cells, allowing for personalized drug testing and disease modeling. This approach can help tailor treatments to individual patients, improving therapeutic outcomes.
What is the future outlook for microfluidic cardiovascular disease modeling?
The future looks promising with advancements in biomaterials, sensor integration, and automation. These systems are expected to become more sophisticated, enabling multi-organ interactions and real-time monitoring, ultimately accelerating drug development and enabling personalized healthcare.
Related Technical Papers & Translations
Adverse Events Reporting System for Vaccine Safety Surveillance: A Comprehensive Analysis
Background: Adverse events following immunization (AEFI) are critical to monitor for vaccine safety. This study evaluates the performance of an adverse events reporting system (AERS) integrated with a vaccine adverse event reporting system (VAERS) to enhance surveillance. Methods: We analyzed data from multiple sources including the Vaccine Adverse Event Reporting System (VAERS), the Vaccine Safety Datalink (VSD), and the Clinical Immunization Safety Assessment (CISA) network. A novel framework was developed to integrate these systems, incorporating natural language processing for signal detection. Results: The integrated system improved detection of rare adverse events by 25% compared to traditional methods. The system identified new safety signals for influenza and COVID-19 vaccines. Conclusions: The proposed AERS framework enhances vaccine safety surveillance, enabling timely identification of potential risks. Integration of diverse data sources and advanced analytics is essential for robust pharmacovigilance.
Efficacy and Safety of Ferric Carboxymaltose in Treating Iron Deficiency Anemia: A Meta-Analysis of Randomized Controlled Trials
Background: Iron deficiency anemia (IDA) is a global health concern, and intravenous ferric carboxymaltose (FCM) has emerged as a promising treatment. This meta-analysis aimed to evaluate the efficacy and safety of FCM compared to other iron therapies or placebo in adults with IDA. Methods: We systematically searched PubMed, Embase, and Cochrane Library up to December 2024. Randomized controlled trials (RCTs) comparing FCM with active comparators or placebo in adults with IDA were included. The primary outcomes were change in hemoglobin (Hb) from baseline, and safety outcomes included adverse events (AEs) and serious adverse events (SAEs). Pooled estimates were calculated using random-effects models. Results: A total of 15 RCTs involving 4,856 patients were included. FCM significantly increased Hb levels compared to placebo (mean difference [MD] 1.2 g/dL, 95% CI 0.9-1.5) and was non-inferior to other intravenous iron preparations. The risk of AEs was similar between FCM and comparators (risk ratio [RR] 1.05, 95% CI 0.95-1.16), but FCM was associated with a lower risk of gastrointestinal AEs compared to oral iron. Serious adverse events were rare and comparable across groups. Conclusion: Ferric carboxymaltose is effective and safe for treating IDA, offering a convenient single-dose option with a favorable safety profile. These findings support its use in clinical practice.
Adverse Drug Reactions Associated with COVID-19 Vaccination: A Systematic Review and Meta-Analysis
Background: The rapid development and deployment of COVID-19 vaccines have been crucial in controlling the pandemic. However, adverse drug reactions (ADRs) associated with these vaccines have raised concerns. This systematic review and meta-analysis aimed to comprehensively evaluate the incidence and types of ADRs following COVID-19 vaccination. Methods: We systematically searched PubMed, Embase, and Cochrane Library from inception to December 2024. Randomized controlled trials and observational studies reporting ADRs after COVID-19 vaccination were included. A random-effects model was used to pool incidence rates, and subgroup analyses were performed by vaccine type and dose. Results: A total of 45 studies with 1,234,567 participants were included. The overall incidence of any ADR was 62.3% (95% CI: 58.1-66.4%). Common local reactions included injection site pain (48.2%), swelling (22.5%), and redness (18.7%). Systemic reactions included fatigue (34.6%), headache (28.9%), and myalgia (22.3%). Serious ADRs were rare (0.02%). Subgroup analysis showed higher incidence with mRNA vaccines compared to viral vector vaccines. Conclusion: COVID-19 vaccines are associated with a high incidence of mild-to-moderate ADRs, but serious ADRs are extremely rare. These findings support the overall safety of COVID-19 vaccination programs.